WE CLAIM:

1. Novel ω-naphthyloxy amino alkane derivatives having structural formula I,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl; a branched chain lower alkyl such as isopropyl, isobutyl, t-butyl and alkyl chains thereof.; a cyclic alkane such as cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl and cyclic alkanes thereof.; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue selected from group comprising of phenyl, substituted phenyl, naphthyl; an arylalkyl residue selected from group comprising of benzyl, substituted benzyl, form a part of a heterocylic ring selected from group comprising of pyrrolidine, piperidine, form a heterocylic ring with additional heteroatoms O,N,S selected from group comprising of piperazine, morpholine, oxazole, oxathinazole, oxathiazine etc.; an alkoxy carbonyl alkane selected from R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above.

2. Novel ω-naphthyloxy amino alkane derivatives as claimed in claim 1 includes:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine

[I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl amine.[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester. [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl ,n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propylamine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]

3. Derivatives as claimed in claim 1, wherein said derivatives are useful for treatment and prevention of hyperglycemia and cardiovascular disorders (CVS) in mammals, including humans.
4. Derivatives as claimed in claim 1, wherein the said derivatives can be administered as pharmaceutical composition optionally along with acceptable salt/s, carrier/s or dilutent/s.
5. Derivatives as claimed in claim 4, wherein the salts/carriers/diluents are selected from a group comprising of lactose sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate or calcium bicarbonate.
6. Derivatives as claimed in claim 1 wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.,
7. Derivatives as claimed in claim 6 wherein, the dosage of the said derivatives is preferably about 300 μmol/Kg.
8. Derivatives as claimed in claim 1, wherein said derivatives may be administered in form syrup, capsule, tablet, intravenous, liquid or suspension.

9. Derivatives as claimed in claim 1, wherein method of administration for said derivatives may be oral, nasal, rectoral, or parenteral.
10. Derivatives as claimed in claim 1, wherein said derivatives lower the concentration of cholesterol by about 30%.
11. Derivatives as claimed in claim 10, wherein said derivatives lower the concentration of cholesterol preferably by about 26%.
12. Derivatives as claimed in claims 1 wherein said derivatives lower the concentration of phospholipid by about 35 %.
13. Derivatives as claimed in claim 12, wherein said derivatives lower the concentration of phospholipid preferably by about 30%.
14. Derivatives as claimed in claim 1 wherein said derivatives lower the concentration of Triglyceride by about 50 %.
15. Derivatives as claimed in claim 14 wherein said derivatives lower the concentration of Triglyceride preferably by about 48%.
16. Derivatives as claimed in claim 1 wherein said derivatives enhance the concentration of high-density lipoprotein (HDL by about 20 %.
17. Derivatives as claimed in claim 16 wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.
18. Derivatives as claimed in claim 1 wherein said derivatives lowers the glucose (GLU) concentration by about 35 %.
19. Derivatives as claimed in claim 18 wherein said derivatives lower the glucose concentration preferably by about 30%.
20. Derivatives as claimed in claim 1 wherein said derivatives lowers the glycerol (GLY) concentration by about 20 %.
21. Derivatives as claimed in claim 1 wherein said derivatives lowers the glycerol (GLY) concentration preferably by about 14 %.
22. Derivatives as claimed in claim 1 wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.
23. Derivatives as claimed in claim 22 wherein, the derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

24. A method for preparing ω-naphthyloxy amino alkane derivatives having structural formula I,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl; a branched chain lower alkyl such as isopropyl, isobutyl, t-butyl etc.; a cyclic alkane such as cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl etc.; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue such as phenyl, substituted phenyl, naphthyl; an arylalkyl residue such as benzyl, substituted benzyl, form a part of a heterocylic ring such as pyrrolidine, piperidine, form a heterocylic ring with additional heteroatoms O,N,S such as piperazine,morpholine, oxazole, oxathinazole , oxathiazine etc.; an alkoxy carbonyl alkane such as R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, said process comprising steps of:

(b) reacting substituted β-naphthol of Formula II with dihaloalkane of formula III in an organic solvent in the presence of a base to obtain an intermediate compound of formula IV, and



Wherein R_1 and R_2 are defined as above and wherein X_1 and X_2 may be same or different halogens, and

(c) reacting compound of formula IV with an amine of formula V in presence of an acid binding agent optionally in an organic solvent to obtain compound of formula I, wherein X_2 is a halogen and R_3 and R_4 are defined as above.

25. A method as claimed in claim 24, wherein said derivatives includes:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl amine.[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester. [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl ,n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propylamine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]

26. A method as claimed in claim 24, wherein the organic solvents in step (a) are selected from group comprising of dry acetone, ethanol, methanol, dimethyl sulphoxide (DMSO), dimethylformamide (DMF), Hexamethylphosphoric triamide (HMPA), acetonitrile or other organic compounds.
27. A method as claimed in claim 24, wherein the base in step (a) is selected from a group comprising of cesium carbonate, potassium carbonate, sodium carbonate, lithium carbonate or other bases.
28. A method as claimed in claim 24, wherein the organic solvents in step (b) are selected from group comprising of dimethyl sulphoxide (DMSO), dimethylformamide (DMF), Hexamethylphosphoric triamide (HMPA) or acetonitrile.
29. A method as claimed in claim 24, wherein the temperature in step (a) is in range of about 50°C to 100°C,
30. A method as claimed in claim 29, wherein the temperature is preferably in the range of about 60°C to 80°C.
31. A method as claimed in claim 24, wherein the temperature in step (b) in the range of about 120°C to 180°C.
32. A method as claimed in claim 31, wherein the temperature is preferably in the range of about 130°C to 150°C.
33. A method as claimed in claim 24, wherein the reaction time in steps (a) and (b) is in range of about 4 hours to 13 hours.
34. A method as claimed in claim 33, wherein the reaction time in steps (a) and (b) is in range of about 5 hours to 12 hours.
35. A method as claimed in claim 24, wherein the derivatives of formula (1) have their melting points in the range of about 75°C to 170°C.

36. A method as claimed in claim 35, wherein the derivatives of formula (1) have their melting points in the range of about 78°C to 160°C.

37. A method as claimed in claim 24, wherein the purity of the said derivatives of formula (1) is in the range of about 80% to 100%.

38. A method as claimed in claim 24, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.

39. A method as claimed in claim 38, wherein the dosage of the said derivatives is preferably about 300 μmol/Kg.

40. A method as claimed in claim 24, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.

41. A method as claimed in claim 40, wherein the method of administration of said derivatives are oral, nasal, or parenteral.

42. A method as claimed in claim 24, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

43. A method as claimed in claim 42, wherein said derivatives lowers the concentration of cholesterol preferably by about 26%.

44. A method as claimed in claim 24, wherein said derivatives lower the concentration of phospholipid by about 35 %.

45. A method as claimed in claim 44, wherein said derivatives lower the concentration of phospholipid preferably by about 30%.

46. A method as claimed in claim 24, wherein said derivatives lower the concentration of triglyceride by about 50 %.

47. A method as claimed in claim 46, wherein said derivatives lower the concentration of triglyceride preferably by about 48%.

48. A method as claimed in claim 24, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

49. A method as claimed in claim 48, wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.

50. A method as claimed in claim 24, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

51. A method as claimed in claim 50, wherein said derivatives lower the glucose (GLU) concentration preferably by about 30 %.

52. A method as claimed in claim 24 wherein said derivatives lower the glycerol (GLY) concentration by about 20 %.

53. A method as claimed in claim 52 wherein, the dosage of the derivatives lowers the glycerol concentration by about 14 %.

54. A method as claimed in claim 24, wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

55. A method as claimed in claim 54, wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

56. A pharmaceutical composition for the treatment or prevention of cardiovascular disorders (CVS) and of hyperglycemic condition (diabetes) in mammals, including humans, said composition comprising of administering effective dosage of ω-naphthyloxy amino alkane derivatives having structural Formula 1,



I

Wherein, R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl; a branched chain lower alkyl such as isopropyl, isobutyl, t-butyl etc.; a cyclic alkane such as cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl etc.; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue such as phenyl, substituted phenyl, naphthyl; an arylalkyl residue such as benzyl, substituted benzyl, form a part of a heterocylic ring such as pyrrolidine, piperidine, form a heterocylic ring with additional heteroatoms O,N,S such as piperazine,morpholine, oxazole, oxathinazole , oxathiazine and compounds thereof; an alkoxy carbonyl alkane such as R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3)

and R_7 is a lower alkyl as defined above, optionally along with acceptable salt/s, carrier/s or dilutent/s.

57. A composition as claimed in claim 56, wherein the salts/carriers/diluents are selected from a group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate or calcium bicarbonate.

58. A composition as claimed in claim 56 wherein, said derivatives include:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl amine.[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester. [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl ,n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : $R_1 = R_2 = R_3$ =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : $R_1 = R_2 = R_3$ = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : $R_1 = R_2 = R_3$ = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propylamine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]

59. A composition as claimed in claim 56, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.

60. A composition as claimed in claim 59, wherein the dosage of the said derivatives is preferably about 300 μmol/Kg.

61. A composition as claimed in claim 56, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.

62. A composition as claimed in claim 56, wherein the method of administration of said derivatives are oral, nasal, or parenteral.

63. A composition as claimed in claim 56, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

64. A composition as claimed in claim 63, wherein said derivatives lowers the concentration of cholesterol preferably by about 26%.

65. A composition as claimed in claim 56, wherein said derivatives lower the concentration of phospholipid by about 35 %.

66. A composition as claimed in claim 65, wherein said derivatives lower the concentration of phospholipid preferably by about 30%.

67. A composition as claimed in claim 56, wherein said derivatives lower the concentration of triglyceride by about 50 %.

68. A composition as claimed in claim 67, wherein said derivatives lower the concentration of triglyceride preferably by about 48%.

69. A composition as claimed in claim 56, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

70. A composition as claimed in claim 69, wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.

71. A composition as claimed in claim 56, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

72. A composition as claimed in claim 71, wherein said derivatives lower the glucose (GLU) concentration preferably by about 30 %.

73. A composition as claimed in claim 56 wherein, said derivatives lowers the glycerol (GLY) concentration by about 20 %.

74. A composition as claimed in claim 73,wherein said derivatives lowers the glycerol concentration by about 14 %.

75. A composition as claimed in claim 56 wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

76. A composition as claimed in claim 75 wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.

77. A method for treatment or prevention of cardiovascular disorders and hyperglycemia (diabetes) by administering pharmaceutical effective dosage of ω-naphthyloxy amino alkane derivatives having structural Formula 1,



I

Wherein R_1 and R_2 are individually H, a lower alkyl containing 1-6 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl; a branched chain lower alkyl such as isopropyl, isobutyl, t-butyl etc.; a cyclic alkane such as cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl etc.; a lower alkoxy in which the alkyl group is as mentioned above, n is 1 to 6; R_3 and R_4 are individually H, a lower straight or branched chain alkyl containing 1-15 carbon atoms as mentioned above; a cyclic alkane as defined above; an aryl residue such as phenyl, substituted phenyl, naphthyl; an arylalkyl residue such as benzyl, substituted benzyl, form a part of a heterocylic ring such as pyrrolidine, piperidine, form a heterocylic ring with additional heteroatoms O,N,S such as piperazine,morpholine, oxazole, oxathinazole , oxathiazine and compounds thereof; an alkoxy carbonyl alkane such as R_6COOR_7, wherein R_6 is $(CH_2)n$ (n=1-3) and R_7 is a lower alkyl as defined above, optionally along with acceptable salt/s, carrier/s or dilutent/s.

78. A method as claimed in 77, wherein the salts/carriers/diluents are selected from a group consisting of lactose, sodium chloride, potassium chloride, magnesium sulphate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulphate, sodium phosphate, potassium phosphate, magnesium succinate, sodium carbonate, sodium sulfate, potassium acid phosphate or calcium bicarbonate.

79. A method as claimed in claim 77 wherein said the derivatives include:

(i) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy)propyl]amine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=3]

(ii) N-(4-Methoxyphenyl)-N-propyl[3-(naphthalen-2-yloxy) propyl amine.[I: R_1= R_2=H, R_3= propyl R_4= 4-methoxyphenyl, n=3]

(iii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester. [I: R_1=R_2=H, R_3=CH_2COOEt,R_4=4-methoxy phenyl, n=3]

(iv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I:R_1=R_2=R_3=H, R_4= benzyl, n=2]

(v) N-(4-Methoxyphenyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1 = R_2 = R_3 = H, R_4= 4-methoxy phenyl, n=2]

(vi) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1 = R_2 = R_3 =H, R_4=4-methoxy phenyl, n=3]

(vii) N-(4-Methoxyphenyl)-[4-(naphthalen-2-yloxy)butylamine [I:R_1=R_2=R_3=H, R_4= 4-methoxyphenyl, n=4]

(viii) N-(4-Methylphenyl)-[2-(naphthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=2]

(ix) N-(4-Methylphenyl)-[3-(naphthalen-2-yloxy) propyl] amine [I:R_1= R_2= R_3 = H, R_4=4-methyl phenyl, n=3]

(x) N-(4-Methylphenyl)-[4-(naphthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=4-methyl phenyl, n=4]

(xi) N-(3-Methoxybenzyl)-[2-napthalen-2-yloxy)ethyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=2]

(xii) N-(3-Methoxybenzyl)-[3-napthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=3-methoxy benzyl, n=3]

(xiii) N-(3-Methoxybenzyl)-[4-napthalen-2-yloxy)butyl]amine[I:R_1=R_2=R_3=H, R_4=3-methoxy benzyl, n=4]

(xiv) N-Benzyl-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=2]

(xv) N-Benzyl-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1=R_2=R_3=H,R_4= benzyl, n=3]

(xvi) N-Benzyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H,R_4= benzyl, n=4]

(xvii) N-Cyclohexyl-[2-(naphthalen-2-yloxy)-ethyl]amine[I : R_1 = R_2 = R_3 = H, R_4 = cylohexyl ,n=2]

(xviii) N-Cyclohexyl-[3-(naphthalen-2-yloxy) propyl] amine [I : R_1 = R_2 = R_3 =H, R_4 = cylohexyl,n=3]

(xix) N-Cyclohexyl-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2=R_3=H, R_4 = cylohexyl,n=4]

(xx) N-(2-Ethyl-n-hexyl)-[2-(naphthalen-2-yloxy)ethyl]amine [I : R_1 = R_2 = R_3 = H,R_4=2-ethyl n-hexyl, n=2]

(xxi) N-(2-Ethyl-n-hexyl)-[3-(naphthalen-2-yloxy)propyl] amine[I:R_1=R_2= R_3= H, R_4=2-ethyl- n-hexyl, n=3].

(xxii) N-(2-Ethyl-n-hexyl)-[4-(naphthalen-2-yloxy)butyl] amine[I:R_1=R_2=R_3=H ,R_4=2-ethyl- n-hexyl, n=4]

(xxiii) N-(n-Dodecyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2=R_3= H,R_4= n-dodecyl,n=2]

(xxiv) N-(n-Dodecyl)-[3-(naphthalen-2-yloxy)-propyl] amine [I:R_1= R_2 = R_3 = H, R_4=n-dodecyl,n=3]

(xxv) N-(n-Dodecyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I:R_1=R_2= R_3= H,R_4= n-dodecyl,n=4]

(xxvi) N-(Isoamyl)-[2-(naphthalen-2-yloxy)-ethyl]amine [I:R_1=R_2 = R_3 = H,R_4= isoamyl, n=2]

(xxvii) N-(Isoamyl)-[3-(naphthalen-2-yloxy)-propyl]amine[I:R_1=R_2=R_3=H R_4 = isoamyl, n =3]

(xxviii)N-(Isoamyl)-[4-(naphthalen-2-yloxy)-butyl]amine[I : R_1 = R_2 = R_3 = H , R_4 = isoamyl,n=4]

(xxix) N-(3-Phenylpropyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I:R_1=R_2= R_3=H , R_4=2-phenyl ethyl, n=2]

(xxx) N-(3-Phenylpropyl)-[3-(naphthalen-2-yloxy) propyl] amine [I: R_1=R_2=R_3= H, R_4=2-phenylethyl, n=3]

(xxxi) N-(3-Phenylpropyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=2-phenylethyl, n=4]

(xxxii) N-(n-Octyl)-[2-(naphthalen-2-yloxy) ethyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=2]

(xxxiii)N-(n-Octyl)-[3-(naphthalen-2-yloxy) propyl]amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=3]

(xxxiv)N-(n-Octyl)-[3-(napthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-octyl, n=4]

(xxxv) N-(n-Butyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-butyl, n=4]

(xxxvi)N-(n-Propyl)-[4-(naphthalen-2-yloxy) butyl] amine [I: R_1=R_2=R_3=H, R_4=n-propyl, n=4]

(xxxvii) N-(2-Phenylethyl)-[2-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl- ethyl, n=4]

(xxxviii) N-(Piperidinyl)-[4-(naphthalen-2-yloxy) butyl] amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=4]

(xxxix)N-(n-Butyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-butyl, n=3]

(xl) N-(n-Propyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2= R_3= H, R_4 = n-propyl, n=3]

(xli) N-(2-Phenylethyl)-[3-(naphthalen-2-yloxy) propyl] amine [I, R_1=R_2=R_3=H, R_4=2-phenyl ethyl, n=3]

(xlii) N-(Piperidinyl)-[3-(naphthalen-2-yloxy) propyl]amine [I, R_1=R_2=R_3=H, R_4= Piperidinyl, n=3]

(xliii) N-(4-Methoxyphenyl)-N-methyl[3-(naphthalen-2-yloxy)propylamine, [I, R_1 = R_2 = H, R_3= methyl, R_4=4-methoxyphenyl, n=3]

(xliv) N-(4 Methoxyphenyl)-N-ethyl[3-(naphthalen-2-yloxy) propyl amine. [I, R_1=R_2=H, R_3= ethyl, R_4=4-methoxyphenyl, n=3]

(xlv) N-(4-Methoxyphenyl)-N-propyl [3-(naphthalen-2-yloxy) propyl amine [I, R_1=R_2=H, R_3= propyl, R_4= 4-methoxyphenyl, n=3]

(xlvi) N-(4-Methoxyphenyl)-N-butyl[3-(naphthalen-2-yloxy) propyl amine[I,R_1=R_2=H, R_3= n-butyl, R_4=4-Methoxyphenyl, n=3]

(xlvii) N-(4-Methoxyphenyl)-[3-(naphthalen-2-yloxy) propyl] amino} acetic acid ethyl ester[I, R_1=R_2=H, R_3= -CH_2COOEt, R_4=4-Methoxyphenyl, n=3]

(xlviii) 2,7-Bis[3-(4methoxyphenylamino)propyloxy]naphthalene[I,R_1=4-methoxyphenyl amino propyloxy, R_2 & R_3=H, R_4= 4-methoxyphenyl]

(xlix) 2,6-Bis[3-(4-methoxyphenylamino)propyloxy]naphthalene[I,R_2=4-methoxyphenyl amino propyloxy, R_1 & R_3=H, R_4= 4-methoxyphenyl]

80. A method as claimed in claim 77, wherein the dosage of the said derivatives is in the range of about 250-350 μmol/Kg.
81. A method as claimed in claim 80, wherein the dosage of the said derivatives is preferably about 300 μmol/Kg.
82. A method as claimed in claim 77, wherein the said derivatives may be administered in form of syrup, capsule, tablet, suspension or intravenous.
83. A method as claimed in claim 77, wherein the method of administration of said derivatives are oral, nasal, or parenteral.
84. A method as claimed in claim 77, wherein said derivatives lower the concentration percentage of cholesterol by about 30%.

85. A method as claimed in claim 84, wherein said derivatives lowers the concentration of cholesterol preferably by about 26%.

86. A method as claimed in claim 77, wherein said derivatives lower the concentration of phospholipid by about 35 %.

87. A method as claimed in claim 86, wherein said derivatives lower the concentration of phospholipid preferably by about 30%.

88. A method as claimed in claim 77, wherein said derivatives lower the concentration of triglyceride by about 50 %.

89. A method as claimed in claim 88, wherein said derivatives lower the concentration of triglyceride preferably by about 48%.

90. A method as claimed in claim 77, wherein said derivatives enhance the concentration of high-density lipoprotein (HDL) by about 20 %.

91. A method as claimed in claim 90, wherein said derivatives enhance the concentration of high-density lipoprotein preferably by about 15%.

92. A method as claimed in claim 77, wherein said derivatives lower the glucose (GLU) concentration by about 40 %.

93. A method as claimed in claim 92, wherein said derivatives lower the glucose (GLU) concentration preferably by about 30 %.

94. A method as claimed in claim 77 wherein said derivatives lower the glycerol (GLY) concentration by about 20 %.

95. A method as claimed in claim 94 wherein said derivatives lower the glycerol concentration by about 14 %.

96. A method as claimed in claim 77, wherein said derivatives lower the glucose concentration in about 30 min to 10 hours during post drug administration.

97. A method as claimed in claim 96, wherein said derivatives lower the glucose concentration in about 1 hr to 7 hrs during post drug administration.